In February 1995, single-dose azithromycin was given to children with trachoma and their household contacts who were children. For children with trachoma, rates of carriage of pneumococci immediately before treatment with azithromycin and 2-3 weeks, 2 months, and 6 months after treatment were 68% (54 of 79), 29% (11 of 38), 78% (29 of 37), and 87% (34 of 39), respectively.
Following successful use overseas, azithromycin has recently been included in Australian antibiotic guidelines as an alternative antimicrobial for treatment of trachoma [1] . In Australia, azithromycin has been evaluated as a single-dose treatment for endemic childhood trachoma in cases and child contacts in a remote Aboriginal community [2] . Azithromycin has also been considered for treatment of other bacterial infections in Aboriginal populations [3] with high rates of pneumococcal invasive disease [4] , with chronic otitis media in association with high nasopharyngeal carriage rates [5] , and with rheumatic heart disease and poststreptococcal glomerulonephritis following group A streptococcal skin infections [6] .
However, patterns of antibiotic use are likely to influence the prevalence of specific antimicrobial resistance [7, 8] , by mechanisms that are poorly understood. For example, pilot studies of amoxicillin treatment of otitis media in an Aboriginal community led to clonal expansion of preexisting multidrug-resistant pneumococcal serotype 6B [9, 10] . Such clonal expansion and spread of resistant pneumococci has also been documented between continents and within a day-care setting [11] [12] [13] .
As part of the trachoma study evaluation [2] , ethical approval was also obtained to concurrently monitor the effect of azithromycin on the carriage and antimicrobial resistance profiles of the bacterial pathogens Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes. We report the impact of azithromycin therapy on S. pneumoniae nasopharyngeal carriage rates, serotype distribution, and frequency of azithromycin-resistant strains.
Methods

Demography, Subjects, and Examination Schedule
We studied children who lived in an Aboriginal community located -800 km southwest of Darwin in the Northern Territory of Australia. Of the total population of 750, there were 221 children aged <15 years. At the initial visit in February 1995, children of primary school age were screened, and of those with trachoma, 79 were swabbed nasopharyngeally immediately before azithromycin therapy. A total of 130 schoolchildren and their household contacts who were children received a single dose (20 mg/kg) of azithromycin.
For the population studied it was anticipated that follow-up, would be difficult because of poor school attendance, particularly after the first month of the school year, which coincided with the commencement of this study. Ethical approval therefore allowed for 80 children to be examined initially and for 40 of these to be examined at the first follow-up visit, with the aim of retaining at least 30 children for each of the 2-month and 6-month follow-up visits. Ethical approval restricted swabbing to no more than 80 trachoma cases involving schoolchildren, with no swabbing of younger cases, contacts, or untreated controls.
Follow-up visits were made 2-3 weeks, 2 months, and 6 months following azithromycin treatment, at which point swab specimens were again obtained (from 38, 37, and 39 children, respectively, from a total cohort of 46 of the original 79 children).
Specimen Handling and Culture Methods
Nasopharyngeal swabs (disposable, cotton-tipped, aluminum shafted products) were gently inserted as far as possible into the nasal cavity, parallel to the roof of the mouth. Swabs were placed in 1.0-mL of skim milk/glucose/glycerol broth [14] and immediately frozen at -10°C to -20°C. Within 4 days of collection, specimens were packed on dry ice, flown to Darwin, and stored at -70°C.
For isolation of S. pneumoniae, swabs were thawed and mixed, and aliquots (10 pt) of broth were plated onto Columbia horse blood agar with and without colistin sulphate-naladixic acid (CNA) selective supplement (Unipath, Basingstoke, England). The detection of multidrug (including azithromycin)-resistant serotype 6B clones was attempted by the culturing of 100-p,L aliquots of broth onto CNA Columbia medium containing chloramphenicol (1.5 pg/mL) [8, 9] . S. pneumoniae isolates were identified by colony morphology, susceptibility to optochin (BBL, Cockeysville, MD), and capsular type.
MICs of azithromycin and erythromycin were determined by means of the Etest (AB BIODISK, Solna, Sweden) [15] , and resistance was defined by MICs of a 2 ug/mL and pg/mL, respectively [16] . S. pneumoniae isolates were serotyped by the capsular swelling (Quellung) method with antisera from the Statens Seruminstitut (Copenhagen) [17] .
carried out with the GLIM statistical package [20] . xi . means x2 with 1 degree of freedom.
Results
Pneumococcal Carriage Rate
The rate of nasopharyngeal carriage of S. pneumoniae was 68% (54 of 79) at the time of the initial trachoma screening visit. Two to 3 weeks following the single dose of azithromycin, the carriage rate had fallen to 29% (11 of 38). At the 2-month and 6-month follow-up visits, the carriage rate had risen to greater than pretreatment levels (78% [29 of 37] and 87% [34 of 39], respectively). The observed fall and then rise in carriage rate was highly significant (x3 = 13.3, P < .001; see table 1 ). The increased carriage from before azithromycin treatment (68%) to 2 months afterward (78%) was not significant (xi = 1.24, P = .26); however, the carriage rate at 6 months after azithromycin treatment (87%) was significantly higher than that before treatment (xi = 4.88, P = .027).
Age and Initial Pneumococcal Carriage Rates in the FollowedUp and Lost-to-Follow-Up Groups
The average age of 27 children lost to follow-up was 9.6 years (range, 5-15 years). The birth dates of six children were not obtained. The average age of 46 children who were seen at least twice during the study was 9.0 years (range, 5-14 years). The pretreatment pneumococcal carriage rate was 66.7% (30 of 45) for the follow-up group, compared with 68.4% (54 of 79) for the entire pretreatment group (table 1).
Additional Antibiotic Use
No additional azithromycin was used in the community before or during the follow-up period. Three of the 46 children (subjects 53, 101, and 159) in the follow-up cohort and two of 27 children lost to follow-up received antibiotics during the period between the single azithromycin dosing and the 2-3-week follow-up visit.
Statistical Analysis
To explore the relationship of pneumococcal serotype colonization to azithromycin use in longitudinal data, changes in colonization status over time were modeled to fit the observed changes in carriage over time and to distinguish reemergence of preexisting strains from acquisition of new strains. Separate rate constants were fitted for susceptible and resistant serotypes.
Likelihoods were calculated from the explicit forms of linear differential equations, and the SEARCH algorithm of Dr. Ken Lange [18] , within the new computer package EPIMOD [19] , was used to obtain maximum likelihood estimates and standard errors for each parameter. Other statistical analyses were
Azithromycin-Resistant Pneumococci: Carriage Rate
One (1.3%) of the original 79 children swabbed was colonized by azithromycin-resistant S. pneumoniae before azithromycin was introduced to the community. Two to 3 weeks post-treatment, the carriage rate of azithromycin-resistant pneumococci had risen to 15.8% of children (6 of 38). This rose further by the 2-month visit to 27% (10 of 37) but subsequently fell to 5.1% (2 of 39) at the 6-month visit (table 1) .
The proportion of pneumococcal carriers with azithromycinresistant strains was 6 of 11 (54.5%) at 2-3 weeks after treatment, decreasing to 10 of 29 (34.5%) and then 2 of 34 (5.9%) at 2 and 6 months post-treatment, respectively (table 1). * Tendency for pneumococcal carriage rate to fall and then rise after treatment: x3 = 13.3, P < .001. t Tendency for frequency of resistant pneumococci to rise and then fall after treatment: x3 = 18.9, P < .001. Tendency for the proportion of resistant pneumococci to rise and then fall after treatment: x3 = 22.4, P < .001.
Selective Plates
No multidrug-resistant serotype 6B pneumococcal clones were found, neither by standard methods nor with the use of chloramphenicol plates and larger inocula.
Frequency and Distribution of Pneumococcal Serotypes
Serotypes of S. pneumoniae isolates before treatment and at 2-3 weeks, 2 months, and 6 months post-treatment are listed in table 2. Overall, 30 serogroups and types were identified among 125 isolates tested. Seven isolates were not typed.
The most prevalent of the 25 serogroups and types recovered before treatment were (in order of decreasing frequency) 22F, 6A, 16, 1, 13, 11A and 33F (30 [53.6%] of 56 typed isolates). At 2-3 weeks post-treatment, only four of the original serotypes were recovered (9V, 22F, 45, and azithromycin-resistant 23A), and a new serotype, 10F, which was resistant to azithromycin, was the most common serotype recovered (5 of 11; 45.5%). At 2 months, 14 types/groups were identified among 28 typed isolates. Eight (28%) belonged to 23A and 10F, and all were azithromycin-resistant. Twelve of the original 25 types were not detected at this time, including those that were of high frequency prior to treatment (22F, 1, 13, 11A, and 33F). A new acquisition, type 8, was identified.
The changed profile of serotypes identified before and 2 months after treatment was significant even after adjustment for the effect of azithromycin-resistant strains (X 8 = 36.75, P < .01). At six months, 17 serotypes were identified, although azithromycin-resistant serotypes 23A and 45 were not detected.
Serotypes of and MICs for Azithromycin -Resistant Isolates
Eighteen isolates of azithromycin-resistant S. pneumoniae were recovered after azithromycin treatment: 6 at 2-3 weeks, 10 at 2 months (1 not typed), and 2 at 6 months. These were confined to types 1OF (10 strains), 23A (6 strains), and type 45 (1 strain). Only one azithromycin-resistant isolate, type 23A, was recovered in low numbers before treatment.
Three children were colonized by azithromycin-resistant strains on consecutive occasions; one child (subject 63) was colonized by serotype 1OF at the 2-week visit and then by 23A at the 2-month visit. The other two children had persistent carriage of the same serotypes: 23A (subject 161) and 1OF (subject 113), respectively (tables 3 and 4). Five isolates of serotype 45 were recovered from four children; only the isolate recovered at the 2-month follow-up visit was resistant to azithromycin (table 2), and this was detected in a child (subject 115) with no prior history of serotype 45 carriage (tables 3 and 4).
MICs of azithromycin and erythromycin were determined by Etest for azithromycin-resistant isolates; the values ranged from 2 pg/mL to _.256 p,g/mL (table 5). These MICs were serotype-dependent; the respective MICs of azithromycin and erythromycin for serotype 23A isolates were _.-256 ,ug/mL and 128 11g/ mL , and those for 1OF isolates were in the range of 16-32 ,ug/mL and 8-16 pg/mL.
Rates of Acquisition and Clearance of Pneumococci
Longitudinal data are presented in tables 3 and 4. Of 37 subjects seen both before treatment and 2-3 weeks later, resistant strains were found in 6 (subjects 61, 63, 113, 123, 132, and 161) of 26 previously colonized subjects but in none of 11 previously noncolonized subjects (table 3) . Similarly, of 34 subjects seen at the 2-month visit, 31 had also been seen before treatment and at 2-3 weeks after azithromycin treatment. Resistant strains were found at 2 months in seven of 25 previously colonized subjects. One additional resistant strain was detected in subject 92, who had not been seen prior to treatment but was previously colonized with azithromycin-susceptible strains at 2-3 weeks.
Thus, 8 resistant isolates (from subjects 63, 67, 78, 113, 137, 161, 173, and 92) were recovered from among 25 previously week" for clearance, corresponding to a mean lag/waiting time 3 and 4) in carriers yielded estimates of K1 = 0.207 (± 0.067) week -1 and K2 = 0.0377 (± 0.0185) week" (manuscript in preparation).
For six of 37 subjects apparently acquiring an azithromycinresistant strain in the first 2-3 weeks after treatment, the apparent acquisition rate (K1) was 0.0812 (± 0.033) week". In the subsequent period, before the 2-month follow-up, additional azithromycin-resistant strains were acquired by six of 28 atrisk children, corresponding to a lesser acquisition rate (K1) of 0.0482 (± 0.020) week-1. * Visit no. 1 = before azithromycin therapy; 2 = 2-3 w following therapy; 3 = 2 mo following therapy; and 4 = 6 mo following therapy.
_---t MIC of 1 Ag/mL indicated resistance. 1 MIC of u2 p,g/mL indicated resistance.
The overall rate of pneumococcal acquisition (K 1 = 0.248 ± 0.061 week -1 ) is potentially contributed by as many as 28 different serotypes (table 2) , corresponding to average strainspecific acquisition rates as low as 0.009 week'. In contrast, the two or three azithromycin-resistant strains were acquired at a rate of 0.081 week' in the immediate posttreatment period (i.e., 0.027 week' per strain) and a rate of 0.048 week" (or 0.016 week -1 per strain) in the second follow-up period.
Discussion
We have shown a significant reduction in the carriage of pneumococci following a single 20 mg/kg dose of azithromycin, particularly with regard to azithromycin-susceptible strains (table 1) . However, this reduction was short-lived (<2 months) and was parallelled by a highly significant rise and then fall in the proportion and frequency of pneumococcal strains resistant to azithromycin. Furthermore, at 6 months, the overall pneumococcal carriage rate (87%) had rebounded to a higher level than before treatment (68%). This trend was of NOTE. NST = not serotyped; -= negative for S. pneumoniae.
marginal significance (P < .027). If real, it could reflect a of pneumococcal carriage. To our knowledge the only other report on the effect of azithromycin on carriage of respiratory bacterial pathogens is that of Adegbola et al., who reported that on day 28, following 3 dosings of azithromycin (20 mg/kg on days 0, 7, and 14), S. pneumoniae but not H. influenzae was eradicated from the oropharynx [21] .
Theoretically, the lag time between pneumococcal clearance and reappearance following azithromycin treatment should depend on the rates of recolonization and of cross-infection from those not receiving azithromycin, as well as on the prevalence of azithromycin-resistant strains persisting in treated individuals. Because of the low frequency of resistant strains prior to treatment, the high apparent rate of acquisition for azithromycin-resistant strains (0.027 week' per strain) following treatment, in comparison with the overall acquisition rate (0.009 week-1 per strain), suggests that resistant strains were acquired through growth of previously hidden strains (see below), rather than through cross-infection alone.
This possibility, which needs testing with additional data, is consistent with the low rate of subsequent occurrence of azithromycin-resistant strains in subjects who previously were not colonized (1 of 7, table 4), compared with the higher rate (8 of 25) in those previously colonized with a susceptible strain. It is likely that azithromycin-resistant strains were hidden as minority strains behind susceptible majority strains but were revealed by the selective effects of treatment.
This interpretation is consistent with previous evidence of concurrent colonization by multiple pneumococcal serotypes [9, 10, [22] [23] [24] . It is also supported by the detection of low numbers of an azithromycin-resistant serotype (23A) in one subject before treatment and by analogous experiments showing that a serotype 6B clone of a pneumococcus with resistance to chloramphenicol and other antibiotics can be revealed against a background of other serotypes with use of a selective antibiotic plate [9, 10] .
Although on the basis of the present evidence we cannot exclude the possibility that the rapid emergence and spread of resistance to azithromycin are due to genetic or epigenetic mechanisms, we believe that the selective stimulus of azithromycin, acting on preexistent resistant-but-hidden strains, is likely to be of greater importance.
We also note that the serotypes associated with azithromycin resistance in this population were not those commonly associated with carriage in children; antibiotic resistance in serotypes 10F, 23A, and 45 has not previously been described. In recent reports from Spain and Belgium, erythromycin resistance was associated with the pediatric serogroups or types 14, 23 (factor type not reported), 6, and 19 and was also found in isolates of types/groups 1, 13, and 9 [25, 26] .
South African isolates of types 6B, 14, and 19F have been known to be resistant to erythromycin and tetracycline but susceptible to penicillin [7] . In the United States, serotype 14 was associated with resistance to penicillin and other antimicrobials. Type 14 may be more receptive to the conjugative transposon Tn1545, which carries resistance to erythromycin and tetracycline [27] . Our study shows that less frequent carriage types, such as 10F, 23A, and 45, can also be resistant to erythromycin and azithromycin and can increase in prevalence, at least in the short term, following azithromycin use.
It is intriguing that pneumococcal recolonization typically involved serotypes that differed from those initially carried and that the most prevalent serotypes in the community before treatment (22F, 1, 13, 11A, 33F) were not found 2 months later. However, immunologic data would be needed to decide whether this was due to the development of serotype-specific immune responses.
Further work is needed to determine the value of azithromycin in reducing the endemic load of multiple pneumococcal serotypes in Aboriginal children at high risk of otitis media and respiratory tract infections. While respiratory carriage of pneumococci can be greatly reduced by a single dose of azithromycin and while potentially invasive pneumococcal serotypes can be eradicated (in the short term), preexisting resistant clones gain a selective advantage.
The clinical significance of increased colonization with serotypes 10F, 23A, and 45 cannot be determined from this study. However, group 10 and type 45 pneumococci cause invasive disease in Papua New Guinea [24] . Moreover, overseas trends suggest that as antibiotic-susceptible pneumococci have been eradicated following antibiotic use, residual disease is attributable to serotypes that are resistant to antibiotics, principally the pediatric types [13] .
As the number of disease-associated serotypes is further reduced in some populations, this could ultimately improve the coverage of future pneumococcal conjugate vaccines, provided that the antibiotics used do not select for nonvaccine serotypes. Furthermore, if dominant pneumococcal serotypes are eradicated by future use of the conjugate vaccine, there may be a compensatory increase in the prevalence of previously rare serotypes, just as the antibiotic used in this study led to a selective advantage for preexisting but infrequent antibiotic-resistant strains.
Finally, our results provide an important reminder that when an antibiotic is chosen on clinical grounds, its value must be doubly discounted when the existence of resistant strains is known first because of the possibility that the antibiotic will be ineffective in the particular patient and second because of the selective effect of the antibiotic in facilitating the spread of the resistant strain in the population [9, 10] .
At present the use of azithromycin is being restricted in Northern Territory Aboriginal communities to those conditions for which it has a clear advantage over all other available antibiotics, namely, sexually transmitted Chlamydia trachomatis infection, trachoma, and donovanosis [28] .
